Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study.
Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study.
复制标题
DOI：
10.3390/vaccines10091404
复制
发表时间：
2022-08-27
期刊：
影响因子：
7.8
通讯作者：
Gotoh A
中科院分区：
文献类型：
--
作者：
Katagiri S;Akahane D;Otsuki S;Suto A;Yamada A;Suguro T;Asano M;Yoshizawa S;Tanaka Y;Furuya N;Fujimoto H;Okabe S;Gotoh M;Ito Y;Gotoh A
We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in the study. From April 2021 to September 2021, all cases (median age = 58 years) were vaccinated twice. Immunoglobulin G for SARS-CoV-2 spike protein (S-IgG) was measured at three timepoints (before the first VC, 1–5 weeks after the second VC (T1), and approximately 6 months after the second VC (T2)). S-IgG was not observed before the first VC in any participant. At T1, all cases had acquired S-IgG. There were no significant differences in S-IgG levels among groups. A paired sample comparison of median S-IgG titers between T1 and T2 in all groups showed a significant reduction in T2 S-IgG titers. There were no significant differences in S-IgG levels among groups. When all patients were analyzed, those aged ≥58 years had significantly lower S-IgG levels than those aged <58 years at T1. The BNT162b2 vaccine was highly effective in CML patients with or without TKIs, and S-IgG levels were as persistent as those in healthy individuals.
登录
查看更多内容
影响因子：
5.2
作者：
Fujioka Y;Sugiyama D;Matsumura I;Minami Y;Miura M;Atsuta Y;Ohtake S;Kiyoi H;Miyazaki Y;Nishikawa H;Takahashi N
通讯作者：
Takahashi N
影响因子：
7.3
作者：
Hughes A;Yong ASM
通讯作者：
Yong ASM
影响因子：
2.7
作者：
Jung K;Shin S;Nam M;Hong YJ;Roh EY;Park KU;Song EY
通讯作者：
Song EY
DOI：
10.15585/mmwr.mm7038e2
发表时间：
2021-09-24
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Dooling K;Gargano JW;Moulia D;Wallace M;Rosenblum HG;Blain AE;Hadler SC;Plumb ID;Moline H;Gerstein J;Collins JP;Godfrey M;Campos-Outcalt D;Morgan RL;Brooks O;Talbot HK;Lee GM;Daley MF;Oliver SE
通讯作者：
Oliver SE
影响因子：
12.8
作者：
Herzog Tzarfati, Katrin;Gutwein, Odit;Koren-Michowitz, Maya
通讯作者：
Koren-Michowitz, Maya